Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 10 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 11753459

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  2. US 11752214

    Protein-antiviral compound conjugates

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  3. US 11730793

    Sustained release formulations using non-aqueous emulsions

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  4. US 11730150

    Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  5. US 11732024

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  6. US 11732025

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  7. US 11732030

    Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  8. US 11730794

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  9. US 11725034

    IL2 agonists and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 15, 2023 · Expires Aug 10, 2043

    granted
  10. US 11713461

    Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  11. US 11713922

    Target residual moisture content for lyophilized drug product

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  12. US 11707506

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  13. US 11708416

    Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  14. US 11708407

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  15. US 11708415

    Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  16. US 11701427

    Diels-alder conjugation methods

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted
  17. US 11696572

    Non-human animals comprising a humanized ASGR1 locus

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 11, 2023 · Expires Jul 6, 2043

    granted
  18. US 11692032

    Anti-LAG3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  19. US 11684050

    Non-human animals having a humanized programmed cell death 1 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  20. US 11674968

    Methods for identifying free thiols in proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  21. US 11674177

    Kelch domain containing 7B (KLHDC7B) variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  22. US 11673967

    Stabilized formulations containing anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  23. US 11673930

    IL10 agonists and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  24. US 11667701

    Anti-PfRH5 antibodies and antigen-binding fragments thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 6, 2023 · Expires Jun 1, 2043

    granted